I use peptides myself. Reading two death reports about something sold in the same market I buy from is not the same as reading a trial result, and I am not going to write around that. Peptide Decoding exists to document this market as it actually is, which means the good results, the dead ends, and the days like today. Below is what the two reports say, what they do not establish, and what has not been checked.
Two reports reached the FDA describing deaths after people used products sold as retatrutide. One came in July, one in September. Both describe cardiac arrest. The FDA would not say whether it has checked either one. Nobody knows what was in the vials. CBS News got both reports under a records request and could not confirm the details.1
Poison centers logged 862 retatrutide calls in the three months to September. That was up from 460, and 249 before that.1 A call is not an injury. The group that counts the calls says so on its own site.2
In the one trial that measured it, 1,949 people on Lilly's own product, cardiovascular events were not more common than on placebo by any margin the trial could detect. On the narrower of its two endpoints they ran slightly the other way.3
So there are three kinds of evidence here about one drug name, and they do not stand in for each other. The reports say what one person told the FDA. The counts measure phone calls. The trials measure a known drug at a known dose, with a control group. Only the trials tell you about the molecule.
What do the two FDA reports actually say?
Two accounts, filed two months apart, both ending in cardiac arrest.
The first was filed in July by a healthcare professional. It describes a 41-year-old woman with obesity who "went into cardiac arrest," reached a hospital with what was reported as a dangerously fast heartbeat, and "died after multiple approaches to resuscitate her failed." The report lists retatrutide as a "suspect product" obtained "from an unreliable source." It also records that she "was drinking kava" at the time.14
The second reached the agency in September. It describes a 49-year-old patient who died following severe dehydration, malnutrition and cardiac arrest. According to the report, a nurse recommended the drug, sold her vials sourced from an online peptide seller, and advised her on dosing.14
CBS News says these appear to be the first public accounts in the United States alleging that retatrutide, or products claiming to contain it, played a role in a death.5
| July report | September report | |
|---|---|---|
| Age | 41 | 49 |
| Filed by | A healthcare professional | Not stated in the coverage |
| Cause described | Cardiac arrest | Severe dehydration, malnutrition, cardiac arrest |
| Product source described | "An unreliable source" | Vials sold by a nurse, sourced from an online seller |
| Other exposures recorded | Kava | Not stated |
| Verified by FDA | The agency declined to say | The agency declined to say |
| Product contents established | No | No |
From the FDA reports as described by CBS News, which obtained them through a FOIA request, and as independently summarized by two other outlets.154
The kava detail in the first report matters and almost no coverage carried it. When a death report records a second substance taken at the same time, that second substance is a competing explanation, and the report itself cannot rank them. It is one of several reasons the first case stays an open question.
Does a report to the FDA mean the drug caused the death?
No. A report records an association in time.
The FDA Adverse Event Reporting System collects what people tell it. Anyone can file a report: a doctor, a nurse, a manufacturer, a family member, a patient. The agency does not confirm the contents before a report enters the database. A report records an association in time, which is not the same as a cause.
CBS was direct about this. The reports "don't prove that the drugs caused or contributed to patient deaths," "the details aren't verified and it is unclear whether the drug was to blame," and "CBS News was not able to independently verify the information included in the reports."1 The FDA "declined to say whether it has verified any of the information in either reported death," saying only that "We review adverse event reports, gathering additional information when needed."1
There is a practical wrinkle for anyone wanting to check this themselves. The public extract of the FDA's adverse event data, served through the openFDA interface, ran to July 30, 2026 when queried for this page.6 The September report postdates that, so it cannot be in the public data yet. The July one may or may not be, depending on when it was received and processed. CBS obtained both through a records request, not from the public database, and a reader who searches and finds nothing has not established anything either way.
Pieter Cohen, an associate professor at Harvard Medical School, told CBS the obvious next step. The FDA "should do whatever it possibly could do to get their hands on the actual drug" injected by both patients, "and they should get that analyzed."1 Until that happens, the reports stay unresolved.
What was in the vials?
No test result has been published for either product.
Products sold as retatrutide are not made by Eli Lilly, which has never sold the drug to anyone outside a clinical trial. Lilly told CBS the reports "make clear the two individuals were taking black-market retatrutide," and said it has found suspect products containing "too much, too little, or the wrong active ingredient," along with contaminants.15
That is a company statement about products competing with its own, so it carries an obvious interest. It is also consistent with what independent and regulator testing has found, which the next section sets out, and which our guide on buying retatrutide online covers in detail. The point for these two cases is narrower. If the contents of a vial are unknown, then a death following its use cannot be attributed to retatrutide, because retatrutide may not be what went in.
What do the poison center numbers show?
Phone calls went up. Injuries are a separate question, and the data cannot answer it.
CBS reported figures from America's Poison Centers, a nonprofit that coordinates the United States poison center network:
| Quarter | Retatrutide exposure calls |
|---|---|
| January to March 2026 | 249 |
| April to June 2026 | 460 |
| July to September 2026 | 862 |
From CBS News, attributed to America's Poison Centers.1 These quarterly retatrutide figures are not published on the organization's own site, so they could not be verified at source for this page. The organization does publish aggregate GLP-1 figures: 3,633 GLP-1 exposure cases as of April 30, 2025, and 22,966 across 2019 to 2025.2
The word doing the work there is "exposure." America's Poison Centers defines it on its own tracking page: "The term 'exposure' means someone has had contact with the substance in some way," and, in the next line, "Exposures do not necessarily represent poisonings or overdoses."2
So 862 is the number of times someone called a poison center about contact with a product sold as retatrutide in three months. It is not 862 injuries, not 862 hospitalizations, and not a rate, because the denominator, meaning how many people are using the stuff, is unknown.
Why does that quarterly increase need reading carefully?
Because the counting itself only started last year.
CBS noted this in its own reporting. America's Poison Centers "has tallied a steady increase in reported exposures to retatrutide since it began tracking them late last year, which is common for a newly monitored drug."1 A substance that acquires its own tracking code mid-stream generates a ramp as centers learn to use the code, independent of whether anything is actually happening more often.
The organization's own caveats say the rest. Case records "are from self-reported calls." It "is not able to completely verify the accuracy of every report made to member centers." Additional exposures "may go unreported." The data "should not be construed to represent the complete incidence of national exposures to any substance." And on the specific question of whether these numbers will hold: "Poison data are considered preliminary and are subject to change until the dataset for a given year has been locked," with case counts liable to change particularly for novel or emerging substances.2
One more factor the organization names directly: "Poison Center call volume about any given substance is influenced by the public's awareness of the hazard."2 Coverage of retatrutide risk has grown through 2026. Coverage drives calls. Calls are the thing being counted.
None of that means the increase is an illusion. The gray market for this drug has plainly grown, and more use would produce more calls for real reasons. It means the figure cannot carry the weight of showing that the drug became more dangerous between March and September.
What did the controlled trials find about cardiac events?
No excess the trial could detect, in the only one that reported cardiovascular outcomes.
Both FDA reports describe cardiac arrest, so the question a reader has is whether pharmaceutical retatrutide shows a cardiac signal. Lilly reported cardiovascular outcomes from TRIUMPH-3 on July 23, 2026, in a trial of 1,949 participants randomized to retatrutide 9 mg, 12 mg or placebo.3
| Endpoint | Retatrutide | Placebo | Hazard ratio |
|---|---|---|---|
| MACE-5: all-cause death, heart attack, stroke, heart failure event or coronary revascularization | 44 events | 52 events | 0.82 (95.0% CI 0.55 to 1.22) |
| MACE-3: cardiovascular death, heart attack or stroke | 27 events | 23 events | 1.12 (95.0% CI 0.64 to 1.96) |
From the company release, read at source. Doses are reported as the trial administered them and are not guidance.3
Read those two rows together, because they point in opposite directions and both intervals cross 1. The broader endpoint ran numerically in retatrutide's favor. The narrower one ran numerically against it. Neither reaches a difference the trial could call real.
Lilly's own framing is the careful one: major adverse cardiovascular events "occurred less frequently than anticipated in both retatrutide and placebo arms."3 The clause about both arms carries the meaning. Events were rarer than the trial was designed to expect on both sides, which leaves the comparison underpowered instead of reassuring. It is not a finding that the drug protects the heart, and it is not a finding that it harms it. CBS reported that sentence accurately, noting the finding applied to patients on retatrutide "as well as those who got a placebo", and adding that the drug reduced certain measures of cardiovascular risk.1
The release carries two more things that change how the table reads. The trial enrolled people with severe obesity, defined as a BMI of 35 or above, and established cardiovascular disease, which is why cardiovascular events were measurable in it at all and why the result does not transfer to a healthier population.3 And a second, on-treatment analysis, which the company flags as not prespecified, gives MACE-5 a hazard ratio of 0.73 with a confidence interval of 0.47 to 1.12 and MACE-3 a hazard ratio of 0.92 with an interval of 0.51 to 1.65.3 On that analysis both endpoints lean the same way, in retatrutide's favor, and both intervals still cross 1.
What the trials do report, clearly, is that people stop taking it. Discontinuation because of adverse events ran 9.8% at 9 mg and 13.5% at 12 mg in TRIUMPH-3 against 4.8% on placebo, and 4.1%, 6.9% and 11.3% across the three doses in TRIUMPH-1 against 4.9%.37
What has testing found inside vials sold as retatrutide?
A regulator opened one. There was no retatrutide in it at all.
The unanswered question is answerable in principle, and it has a documented precedent. On September 14, 2026, Australia's Therapeutic Goods Administration published results from testing a vial sold as retatrutide after a patient was hospitalized. The product "contained no retatrutide, but instead had undeclared semaglutide", at a level "approximately eight times higher than the level found in semaglutide products assessed by the TGA".8 The patient had experienced uncontrollable vomiting and suffered what the reporting describes as a potentially fatal torn esophagus.8 The TGA's advice was that retatrutide "should not be used outside of a clinical trial setting".8
Hold that case next to the September death report. A massive semaglutide overdose produces violent vomiting. Violent vomiting produces dehydration and an inability to keep food down. The September report describes severe dehydration, malnutrition and cardiac arrest.
That is a documented pathway, not a finding about this case. No test result has been published for the vials in either death report, so no one can say whether something similar happened. The point is narrower and more useful: there is a regulator-verified example of a vial sold as retatrutide containing a different drug at roughly eight times the concentration found in the products that regulator had assessed, and that example produces the clinical picture one of these reports describes. It makes the case for testing the vials. It settles nothing about what occurred.
Broader testing points the same way about contents being unreliable. Leeder Analytical in Australia tested 18 counterfeit retatrutide samples during 2026, with only one matching its label claim. Around 30% carried higher concentrations than stated, around 30% lower, and one vial "contained none of the peptide".9
The part of that record nobody quotes is what else is in the vial. Grace Hamann, an analytical chemist at the same laboratory, told the ABC that the peptide "usually only made up about 10 per cent of what was in the vials", leaving "another 90 per cent that's unaccounted-for, which could contain a different toxin or something else unsafe".9 So the question is not only whether a vial holds the right drug at the right strength. It is what occupies the rest of it, and that has not been characterized.
Documented harm from these products is not limited to the two FDA reports either. Marie Sinclair, a liver transplant specialist, has treated patients in Victoria for liver failure after they took black market peptides labeled as retatrutide, and has facilitated testing of vials taken from patients with severe liver failure.9 Those cases are in a different country and are not connected to the two deaths, and they are the clearest clinician-reported harm in anything read for this page. Our own report on the counterfeit vial case covers the wider picture, including how blind-test records differ by sales channel.
So "nobody knows what was in the vials" is true of these two cases specifically. It is not true that nothing is known about what tends to be in vials sold under this name, and what is known is that the label is frequently wrong about both the drug and the dose.
Why are these three kinds of evidence not interchangeable?
Because each one answers a question the other two cannot.
- An adverse event report records what one person told a government agency about one case. It is a signal to investigate. It establishes no cause, has not been verified, and in these two instances concerns a product of unknown composition.
- A poison center count measures telephone calls about contact with a substance. It is sensitive to awareness, to tracking changes and to publicity, it carries no denominator, and the organization behind it says the figures stay provisional for novel substances.
- A randomized trial measures a known molecule at a known dose in a counted population against a control group. It is the only one of the three that can attribute an effect to a drug, and it is also the only one that tells you nothing whatsoever about what is in a vial bought online.
That last line is the trap. Lilly's trials are evidence about retatrutide. They are not evidence about the products in these two reports, because no one has established that those products were retatrutide. Running the inference in the other direction fails too: two unverified reports about unknown substances are not evidence against the molecule.
Can a purity test tell you a vial is safe?
No, and that mistake is the most common one made with seller testing records.
A certificate of analysis, or a third-party test a seller commissions, addresses identity and purity. At best it tells you that the powder is the compound named and that it is not heavily contaminated with what the test looked for. Our guide on reading a certificate of analysis sets out what those documents do and do not cover, and what a usable one looks like.
What no such test addresses is whether injecting the substance is safe for a person. That requires a trial, with a control group, counting what happens to people. Identity is a manufacturing question. Safety is a clinical question. A clean test result on a vial of a drug that has never been approved for use tells you the vial probably contains an unapproved drug.
The September report illustrates the gap. A licensed clinician reportedly recommended a research-use-only product and advised on dosing. An attorney for the company whose name appeared on a pictured vial said a healthcare professional should never recommend research-use-only products to a patient.4 Whatever testing sat behind that vial, it could not have answered the question being asked of it.
Who sold the products, and what is known about that?
Very little. One named company disputes the connection.
A vial pictured in the September report carried a peptide seller's name and the words "research use only." An attorney for that company told CBS there was not enough information in the redacted report to know whether the company sold the product, and that the pictured vial does not match the company's current packaging.14 This page does not name the seller, because an unverified report and a disputed photograph are not grounds to attach a death to a business.
The wider enforcement picture is active. Lilly filed six suits in August and five more on October 8, and has reported more than 14,000 listings for products claiming to be its drugs to authorities.5 Lilly has said the litigation is needed to avoid "poisoning the well for the future of retatrutide medicines."1 Two of the August cases have since settled, one with a seller that agreed to stop selling the products, tell customers to stop taking them, and donate an undisclosed sum to America's Poison Centers.5 The rest are undecided.
Is retatrutide approved anywhere?
No, nowhere in the world.
Retatrutide has completed Phase 3 trials with strong weight loss results, and Lilly has indicated it intends to seek approval in early 2027.5 Until a regulator reviews it, there is no approved product, no label, no pharmacy supply and no manufacturer standing behind what anybody injects. Everything sold under the name today comes from outside that system.
Cohen put the structural version of the point to CBS: "It is concerning because of the breakdown of our drug-approval process in the United States of America."1
What would actually settle this?
Testing the products, a step no one has reported taking.
The two cases turn entirely on an unanswered question, namely what was in the vials. That question has a method, and a regulator has already run it once on a different vial with a startling result. Obtain the product, test it, publish what was in it. That is what Cohen asked the FDA to do.1 The agency said it reviews reports and gathers additional information when needed, and "generally does not discuss potential or ongoing compliance matters," which is neither a confirmation nor a denial that anything is underway.1
Moving this from an open question to a finding would take a laboratory result on the products involved, a medical examiner's determination in either case, and poison center data with a denominator and a locked dataset behind it. None of that exists publicly today.
Until then, the accurate statement is that two deaths have been reported to the FDA following the use of products sold as retatrutide, that the reports are unverified, that the products are uncharacterized, and that the molecule's controlled trials have not shown a cardiac excess against placebo.
Common questions
Has anyone died from retatrutide?
Two deaths have been reported to the FDA following the use of products sold as retatrutide, one in July and one in September 2026. Neither report has been verified by the FDA, neither product's contents have been established, and no determination has been published that retatrutide caused either death. CBS News says these appear to be the first public accounts in the United States alleging the drug played a role in a death.
Did the FDA confirm that retatrutide caused these deaths?
No. The agency declined to say whether it has verified any of the information in either report, saying only that it reviews adverse event reports and gathers additional information when needed. An adverse event report records what somebody told the FDA. It establishes an association in time, not a cause.
How many retatrutide exposures have been reported to poison centers?
America's Poison Centers logged 862 exposure calls in the three months ending September 2026, 460 in the three months before that, and 249 in the first quarter of 2026, according to CBS News. The quarterly figures are not published on the organization's own site. An exposure call means someone had contact with a substance, and the organization states that exposures do not necessarily represent poisonings or overdoses.
Does the rise in poison center calls mean the drug got more dangerous?
It cannot show that. The organization began tracking retatrutide separately late in 2025, and a newly monitored substance produces a rising count as centers adopt the code. The figures also have no denominator, so they cannot give a risk per person using the drug, and the organization says call volume is influenced by public awareness of a hazard and that counts for novel substances remain provisional.
Do the clinical trials show a heart risk with retatrutide?
Not one the trials could detect. In TRIUMPH-3, with 1,949 participants, the broader cardiovascular endpoint recorded 44 events on retatrutide against 52 on placebo, a hazard ratio of 0.82, and the narrower endpoint 27 against 23, a hazard ratio of 1.12. Both confidence intervals cross 1. Lilly stated that these events occurred less frequently than anticipated in both the retatrutide and the placebo arms, which leaves the comparison underpowered rather than reassuring.
Why can't the trial results tell me whether a vial I bought is safe?
Because the trials tested a known molecule made by the manufacturer at a known dose under medical supervision. They say nothing about the contents of a product bought from an unregulated seller. Lilly says it has found suspect products with too much, too little or the wrong active ingredient, along with contaminants.
Does a certificate of analysis mean a product is safe to inject?
No. Identity and purity testing addresses what is in a vial. Safety in people is a separate question that only a clinical trial answers. A clean test on an unapproved drug tells you the vial probably contains an unapproved drug.
Was a healthcare professional involved?
One report describes it. According to the September report, a nurse recommended the drug, sold the patient vials sourced from an online peptide seller, and advised on dosing. An attorney for the company whose name appeared on a pictured vial said a licensed healthcare professional should never recommend research-use-only products to a patient.
Which seller was named?
A vial pictured in one report carried a seller's name. This page does not repeat it, because an attorney for that company said the redacted report does not establish that it sold the product and that the pictured vial does not match the company's current packaging. An unverified report and a disputed photograph are not grounds to attach a death to a business.
Were these deaths connected to Lilly's trials?
No. Lilly told CBS News that neither case was connected to a clinical trial, and the documents indicate the same.
Can I look these reports up myself?
Probably not, and the public data cannot settle it either way. The public extract of the FDA's adverse event data ran to July 30, 2026 when queried for this page. The September report postdates that, so it cannot be in the extract yet. The July one may or may not be, depending on when it was received and processed. CBS obtained both through a Freedom of Information Act request instead. Searching and finding nothing does not mean the reports do not exist.
Has anyone tested a vial sold as retatrutide and found something else?
Yes. Australia's Therapeutic Goods Administration tested one in September 2026 after a patient was hospitalized and reported that it contained no retatrutide at all, but undeclared semaglutide at approximately eight times the level found in semaglutide products it had assessed. Separately, Leeder Analytical tested 18 counterfeit retatrutide samples during 2026 and found only one matching its label claim, with around 30% stronger than stated, around 30% weaker, and one containing none of the peptide.
Could the deaths have been caused by something other than retatrutide?
Nothing has been established either way, because no test result for either vial has been published. What is on the record is that a regulator found a vial sold as retatrutide containing a different drug at roughly eight times the concentration in the products it had assessed, and that the patient in that case vomited severely enough to tear an esophagus. Severe vomiting leads to dehydration and difficulty keeping food down, which is close to what the September death report describes. That is a pathway on the record. It is not a conclusion about these two cases.
Is retatrutide approved?
No. It is investigational. Phase 3 trials have reported results and Lilly has indicated it intends to seek approval in early 2027. Until a regulator reviews it there is no approved product, no label and no pharmacy supply, which is why everything sold under the name today sits outside the regulated system.
What would it take to know whether the drug was involved?
A laboratory analysis of the products the patients used, a medical examiner's determination in either case, and poison center data with a denominator and a locked dataset. None of those exists publicly. The single most useful step is testing the products, which is what Pieter Cohen of Harvard Medical School told CBS News the FDA should do.
Sources that could not be read for this page
- The redacted FDA adverse event reports themselves. CBS links them as DocumentCloud files. They could not be retrieved, so every detail of both cases on this page is reported as CBS describes it, with two independent summaries cited alongside.
- The FDA's own FAERS caveat page, which carries the agency's standard language on what a report does and does not establish. The proxy rate-limited the request and instructed against retrying. Two other FDA pages were read instead and neither carries the causation language, so the caveats on this page are quoted from CBS News, from Medical Daily's summary and from America's Poison Centers, not from the FDA directly.
- America's Poison Centers quarterly retatrutide figures. Not published on the organization's site. The 249, 460 and 862 counts rest on CBS News reporting alone.
- A donation to America's Poison Centers. An earlier version of this page described this as a Lilly donation and treated it as a possible conflict of interest, because the organization producing the exposure figures would have been taking money from the company those figures help. That was backwards. Becker's reports that a seller Lilly sued agreed to make the donation as part of a settlement, not Lilly. The settlement is now reported in the body and the conflict-of-interest reading has been removed.
Sources
- Gilbert D. Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? CBS News, updated October 13, 2026, 1:38 PM EDT. cbsnews.com. Read at source. The original investigation, based on two FDA adverse event reports obtained through a Freedom of Information Act request. July report: a healthcare professional reported that a 41-year-old woman "went into cardiac arrest", with retatrutide listed as a "suspect product" obtained "from an unreliable source", that she "was drinking kava" at the time, and that she "died after multiple approaches to resuscitate her failed". September report: a 49-year-old patient died following severe dehydration, malnutrition and cardiac arrest after a nurse sold her vials. A pictured vial carried a peptide seller's name and the words "research use only"; an attorney for that company said there "simply wasn't enough information in the redacted report to the FDA" to know whether that company sold the product, and that the vial image "does not match the company's current packaging". Caveats from the article, the first of which appears in the page metadata rather than the body: "While unverified"; the reports "don't prove that the drugs caused or contributed to patient deaths"; "the details aren't verified and it is unclear whether the drug was to blame"; "CBS News was not able to independently verify the information included in the reports"; and the products are described as "products claiming to be retatrutide". FDA "declined to say whether it has verified any of the information in either reported death" and said "We review adverse event reports, gathering additional information when needed" while noting it "generally does not discuss potential or ongoing compliance matters". Poison center figures attributed to America's Poison Centers: 862 exposures in the three months ending September, "up from 460 in the three months prior and 249 in the first three months of 2026", with the organization having "tallied a steady increase in reported exposures to retatrutide since it began tracking them late last year, which is common for a newly monitored drug". Lilly said the reports "make clear the two individuals were taking black-market retatrutide", that suspect products have "too much, too little, or the wrong active ingredient" and "can put patients at serious risk", and that litigation is needed to avoid "poisoning the well for the future of retatrutide medicines". Pieter Cohen, associate professor at Harvard Medical School: "It is concerning because of the breakdown of our drug-approval process in the United States of America"; "The FDA should do whatever it possibly could do to get their hands on the actual drug that was injected by both of these patients, and they should get that analyzed"; and "If the FDA is not aggressively investigating these cases, that's deeply concerning." The second of those was added to this record during a verification pass: the body quoted it from the start, but this footnote had omitted it, so the footnote was not a complete record of what the article carries. The redacted FDA reports themselves are linked from the article as DocumentCloud files, which could not be retrieved for this page.
- GLP-1, Track Emerging Hazards. America's Poison Centers. poisoncenters.org. Read at source. The organization's own definitions and caveats, quoted: "The term 'exposure' means someone has had contact with the substance in some way"; "Exposures do not necessarily represent poisonings or overdoses"; "Case records in this database are from self-reported calls"; "America's Poison Centers is not able to completely verify the accuracy of every report made to member centers"; "Additional exposures may go unreported to Poison Centers"; the data "should not be construed to represent the complete incidence of national exposures to any substance(s)"; "Poison Center call volume about any given substance is influenced by the public's awareness of the hazard"; and "Poison data are considered preliminary and are subject to change until the dataset for a given year has been locked", with case counts liable to change particularly for novel or emerging substances. Published aggregate GLP-1 figures: "As of April 30, 2025, Poison Centers have managed 3,633 GLP-1 agonist related exposure cases" and "From 2019 to 2025, Poison Centers have managed 22,966 GLP-1 agonist related exposure cases", with "a nearly 1,500% increase in calls since 2019". The page does not mention retatrutide and carries no quarterly figures, so the 249, 460 and 862 counts could not be verified at source and are cited to CBS News only.
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Eli Lilly and Company, July 23, 2026. investor.lilly.com. Company release, read at source. TRIUMPH-2 (NCT05929079), 1,152 participants randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg or placebo. TRIUMPH-3 (NCT05882045), 1,949 participants randomized 1:1:2 to retatrutide 9 mg, 12 mg or placebo. Quoted: "major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms." MACE-5, comprising all-cause death, heart attack, stroke, heart failure event or coronary revascularization: 44 events with pooled retatrutide against 52 with placebo, "resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22)". MACE-3, comprising cardiovascular death, heart attack or stroke: 27 against 23, "resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96)". Discontinuation due to adverse events in TRIUMPH-2 was 3.8%, 11.6% and 7.7% across the three doses against 4.9% on placebo, and in TRIUMPH-3 was 9.8% and 13.5% against 4.8%. Deaths are not reported separately; all-cause death appears only inside MACE-5. Serious adverse events are not reported for retatrutide. These are topline results and the release states detailed data will be presented at future meetings. Correction made during a verification pass: an earlier version of this page stated that CBS News had dropped the clause about both arms from this sentence. It had not. CBS reports the finding as applying to patients on retatrutide "as well as those who got a placebo", which is the same substance in plainer words, and also reports that the drug reduced certain measures of cardiovascular risk. The accusation was wrong and has been removed. Also from this release and added during the same pass: TRIUMPH-3 enrolled people with severe obesity, "defined as BMI ≥35 kg/m2, and established cardiovascular disease", with or without type 2 diabetes; a second, on-treatment analysis that the release flags as "not pre-specified" gives MACE-5 a hazard ratio of 0.73, 95% CI 0.47 to 1.12, and MACE-3 a hazard ratio of 0.92, 95% CI 0.51 to 1.65; the trial's primary endpoint was percent change in body weight, reported as −21.6% at 9 mg and −22.6% at 12 mg against −3.2% on placebo; and the release reports average reductions at the top dose of 37.0% in triglycerides, 16.5% in non-HDL cholesterol and 51.2% in hsCRP, with systolic blood pressure down 9.3 mmHg.
- Brooks D. Poison Center Exposures to Bootleg Retatrutide Nearly Double in Three Months as FDA Logs Two Death Reports. Medical Daily, October 14, 2026, 3:28 AM EDT. medicaldaily.com. Read at source. Second independent summary. Confirms the kava detail, the dangerously fast heartbeat on hospital arrival, and that the nurse "recommended the drug, sold her vials from an online peptide vendor, and advised on dosing". Quotes the company attorney: "A licensed healthcare professional should never recommend research-use-only products to a patient." States that adverse event reports "are early warning signals, not proof", that anyone can file one, that details are often incomplete, and that the FDA redacted identifying information in the copies CBS obtained. One source-quality note: this article attributes the quote "The era of snake oil and quack medicine is back" to "Peter Whoriskey, research director of Public Citizen's Health Research Group". That attribution appears to conflate names, so the quote is not used on this page.
- Jeffries E. 2 deaths reported to FDA after people took products claiming to be Eli Lilly's retatrutide: Report. Becker's Hospital Review, October 13, 2026. beckershospitalreview.com. Read at source. Independent summary, attributing the case details to CBS News. Quoted: the reports "were submitted to the FDA's Adverse Event Reporting System and obtained through a Freedom of Information Act request"; "The FDA declined to say whether it has verified either one"; "Lilly told CBS News neither case was connected to a clinical trial"; and that CBS News "said they appear to be the first public accounts in the U.S. alleging retatrutide, or products claiming to contain it, played a role in a death". Adds detail not attributed to CBS: Lilly suits against six companies in August and five on October 8, more than 14,000 reported listings, and a stated plan to seek approval in early 2027. A roughly $100 million annual gray-market figure is attributed only to unnamed "reports estimating" it and is not used on this page.
- openFDA drug adverse event endpoint, queried October 14, 2026. api.fda.gov. Queried directly for this page, then re-queried during a verification pass. The response metadata gives a last-updated date of 2026-07-30 for the public FAERS extract, 20,692,690 records, and the disclaimer "Do not rely on openFDA to make decisions regarding medical care." Correction made during that pass: an earlier version of this page gave the extract's last-updated date as April 28, 2026 and argued from it that neither report could appear in the public data. The current value is July 30, 2026, so the September report cannot be in the extract but the July one may be, and the argument as originally written was wrong. No FAERS record count for retatrutide is asserted anywhere on this page: a query on the non-exact product field returned records unrelated to the drug, indicating the field was matching tokens rather than the name, and a follow-up exact-match query was refused before it could run.
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Eli Lilly and Company, May 21, 2026. investor.lilly.com. Company release, read at source. TRIUMPH-1 (NCT05929066), 2,339 participants randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg or placebo over 80 weeks, with a prespecified extension to 104 weeks for 532 participants with BMI of 35 or above. Discontinuation due to adverse events was "4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg" against "4.9% with placebo". Dysesthesia occurred in "5.1%, 12.3%, and 12.5% of patients" against 0.9% on placebo. Urinary tract infections 7.5% to 8.8% against 5.3%. "The types of adverse events seen were generally consistent with trials of other incretin-based therapies." This release reports no deaths and no cardiac adverse event data, which is why the cardiovascular figures on this page come from the July release at footnote 5.
- Carbonell R. Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings. ABC News (Australia), September 14, 2026. abc.net.au. Read at source, as the reporting route to a regulator finding. The Therapeutic Goods Administration's own safety alert of the same date is robots-disallowed and could not be read directly. Quoted from the ABC report of the TGA testing: the product "contained no retatrutide, but instead had undeclared semaglutide", at a level "approximately eight times higher than the level found in semaglutide products assessed by the TGA", described as "an exceptionally high dose of the drug". The patient "experienced uncontrollable vomiting and required hospitalisation" and "suffered a potentially fatal torn oesophagus"; the report does not give the patient's final condition. TGA advice quoted: retatrutide "should not be used outside of a clinical trial setting". Note this is a separate case in a different country from the two FDA reports, and nothing connects them beyond the product name.
- Carbonell R, Gribbin C, Yu A. New testing of black market peptides reveals dangerous dosing levels. ABC News (Australia), August 28, 2026. abc.net.au. Read at source. Leeder Analytical "tested 18 samples of counterfeit retatrutide this year, with only one matching its label claim", with about 30% at higher concentrations than stated, about 30% lower, and one vial that "contained none of the peptide". A separate three-vial test commissioned by the ABC with the University of Queensland found one vial below its labeled content and two with much higher concentrations. These are counterfeit samples obtained outside a regulated channel and the figures describe that channel, not every product sold under the name. Added during a verification pass, from the same article: analytical chemist Grace Hamann of Leeder Analytical said the peptide "usually only made up about 10 per cent of what was in the vials", with "another 90 per cent that's unaccounted-for, which could contain a different toxin or something else unsafe"; and Marie Sinclair, a liver transplant specialist, "has recently treated patients in Victoria" for liver failure after they took black market peptides labeled as retatrutide, and "has facilitated testing of vials from patients who had severe liver failure".